{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-122511","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.317824+00:00","generated_at":"2026-05-21T01:48:25.714249+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tectonic TX45 Phase 1b in PH-HFpEF shows 19% PCWP reduction, sustained 29-day effects","bullets":["Single IV dose of TX45 reduced PCWP by 19.0% [95% CI, -26.1% to -11.9%] in 19-patient cohort.","In CpcPH subgroup (PVR≥2), PVR decreased 32.0% (≥2) and 35.5% (≥3); 30%+ reduction in PVR.","Echocardiogram showed sustained improvements in TAPSE/SPAP and RVFAC for 29 days post-dose.","Cardiac output increased 18.5% overall; greater improvement in patients with higher baseline PVR.","No serious or severe adverse events; Phase 1b Part B in HFrEF topline expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-122511","json":"https://secwatch.observer/filing/0001193125-25-122511.json","markdown":"https://secwatch.observer/filing/0001193125-25-122511.md","text":"https://secwatch.observer/filing/0001193125-25-122511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525122511/0001193125-25-122511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525122511/d939029d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:48:25.714249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}